The Society of Surgical Oncology, inc.
The American Society of Breast Surgeons.
Annals of Surgical Oncology

Log in | Register

TARGIT-R (Retrospective): North American Experience with Intraoperative Radiation Using Low-Kilovoltage X-Rays for Breast Cancer

Stephanie A. Valente DO, FACS, Rahul D. Tendulkar MD, Sheen Cherian MD, Colin O’Rourke MS, Jon M. Greif DO, Lisa Bailey MD, Valery Uhl MD, Kevin P. Bethke MD, Eric D. Donnelly MD, Ray Rudolph MD, Aaron Pederson MD, Thomas Summer MD, S. Chace Lottich MD, Darrel L. Ross MD, Christine Laronga MD, Loretta Loftus MD, Andrea M. Abbott MD, Pond Kelemen MD, Ulrich Hermanto MD, Neil B. Friedman MD, Gauri C
Breast Oncology
Volume 23, Issue 9 / September , 2016



Single-dose intraoperative radiotherapy (IORT) is an emerging treatment for women with early stage breast cancer. The objective of this study was to define the frequency of IORT use, patient selection, and outcomes of patients treated in North America.


A multi-institutional retrospective registry was created, and 19 institutions using low-kilovoltage IORT for the treatment of breast cancer entered data on patients treated at their institution before July 31, 2013. Patient selection, IORT treatment details, complications, and recurrences were analyzed.


From 2007 to July 31, 2013, a total of 935 women were identified and treated with lumpectomy and IORT. A total of 822 patients had at least 6 months’ follow-up documented and were included in the analysis. The number of IORT cases performed increased significantly over time (p < 0.001). The median patient age was 66.8 years. Most patients had disease that was <2 cm in size (90 %) and was estrogen positive (91 %); most patients had invasive ductal cancer (68 %). Of those who had a sentinel lymph node procedure performed, 89 % had negative sentinel lymph nodes. The types of IORT performed were primary IORT in 79 %, secondary IORT in 7 %, or planned boost in 14 %. Complications were low. At a median follow-up of 23.3 months, crude in-breast recurrence was 2.3 % for all patients treated.


IORT use for the treatment of breast cancer is significantly increasing in North America, and physicians are selecting low-risk patients for this treatment option. Low complication and local recurrence rates support IORT as a treatment option for selected women with early stage breast cancer.

Add a comment

0 comment(s)